Abstract
In an international, multicenter, open-label, randomized comparative study, adult patients in intensive care units were enrolled to receive cefpirome intravenously at 2 g twice daily or ceftazidime intravenously at 2 g three times daily for the empiric treatment of pneumonia. Randomization was performed after a double stratification according to the investigator's initial choice of monotherapy or combination therapy and then on the basis of the severity of disease. The primary endpoint was the clinical response at the end of treatment in the intent-to-treat population. Data for all patients were reviewed by a blinded observer. Of the 400 enrolled patients, 201 received cefpirome (monotherapy, 56%) and 199 received ceftazidime (monotherapy, 51%). Pneumonia was hospital acquired for 75% of the patients. Clinical failures rates were 34 versus 36% (odds ratio = 0.922; upper bound of 90% confidence interval = 1.301) in the intent-to-treat analysis for cefpirome and ceftazidime, respectively. For the cefpirome and ceftazidime groups, there were 35 versus 30% clinical failures among monotherapy-stratified patients, respectively, and 34 versus 42% clinical failures among combination therapy-stratified patients, respectively. The rates ...Continue Reading
References
Dec 11, 1992·Antimicrobial Agents and Chemotherapy·J A KorvickM M Wagener
Jul 1, 1991·Diagnostic Microbiology and Infectious Disease·R N JonesK E Aldridge
Jan 1, 1991·Antimicrobial Agents and Chemotherapy·F BellidoR E Hancock
Feb 1, 1990·Antimicrobial Agents and Chemotherapy·H NikaidoE Y Rosenberg
Nov 1, 1989·The American Journal of Medicine·M HilfR R Muder
Apr 1, 1989·The American Review of Respiratory Disease·J Y FagonC Gibert
Nov 1, 1984·Critical Care Medicine·J R Le GallD Villers
May 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E RubinsteinC Grassi
Aug 1, 1995·Chest·D E Craven, K A Steger
Aug 1, 1994·American Journal of Respiratory and Critical Care Medicine·M S NiedermanW Summer
Jun 1, 1994·Antimicrobial Agents and Chemotherapy·A ComettaO Huber
Mar 1, 1994·Antimicrobial Agents and Chemotherapy·M P FinkG A Siami
Jun 1, 1993·The Journal of Antimicrobial Chemotherapy·S R NorrbyM Glauser
Oct 1, 1993·Chest·J RelloG Prats
Apr 1, 1996·Chest·S Crouch BrewerK V Leeper
Jul 1, 1996·American Journal of Respiratory and Critical Care Medicine·L PapazianF Gouin
May 1, 1996·Intensive Care Medicine·F Alvarez-Lerma
Dec 1, 1996·Intensive Care Medicine·O LeroyG Beaucaire
Citations
Nov 17, 2007·Critical Care Medicine·Mary-Anne W AartsJohn C Marshall
Jul 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marin H KollefJohn Segreti
May 1, 2008·The Journal of Antimicrobial Chemotherapy·R G MastertonMark Wilcox
Apr 26, 2003·Journal of Clinical Pharmacy and Therapeutics·H A DuganR Jung
Nov 16, 2004·Critical Care Medicine·Pierre-Yves BochudThierry Calandra
Oct 13, 2006·Current Opinion in Infectious Diseases·L E Nicolle
Jun 29, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ioannis A BliziotisMatthew E Falagas
Jan 16, 2002·American Journal of Respiratory and Critical Care Medicine·Harald HerknerMarkus Müller
Mar 13, 2002·Critical Care Medicine·Philippe MontraversJean Louis Pourriat
Apr 6, 2002·American Journal of Respiratory and Critical Care Medicine·Jean Chastre, Jean-Yves Fagon
Sep 5, 2012·Expert Opinion on Pharmacotherapy·Sang-Ho Choi, Younsuck Koh